



**INFORMATION ONLY**  
 Privigen® Inventory  
 Customer Letter # 2021-03

2021-01-21

Dear Colleagues:

Further to [CL 2020-50](#) Canadian Blood Services has been advised by CSL Behring that new stock of commercial Privigen® will not be available before July 2021. It is anticipated that commercial Privigen® supply will resume in July 2021; however, this is pending confirmation from CSL Behring.

The table below presents the current available stock for all sizes and the anticipated month of depletion (stock-out). The stock-out months are based on current demand levels without replenishment. If the anticipated new stock is received in July 2021, then Privigen® 5g and 20g vials are not expected to stock-out, while the 2.5g may be affected depending on when we receive the new stock.

CBS Code	Product/Manufacturer	Vial Size	Available	Month of Depletion	New Stock
1000106506	Privigen® 10%, CSL Behring	2.5g	Yes	Jul 21	Anticipated Jul 2021 Pending confirmation on exact allocation from CSL
1000104980	Privigen® 10%, CSL Behring	5g	Yes	Aug 21	
1000104982	Privigen® 10%, CSL Behring	10g	Yes	Mar 21	
1000104983	Privigen® 10%, CSL Behring	20g	Yes	Sep 21	
1000106583	Privigen® 10%, CSL Behring	40g	Yes	Feb 21	

Should you consider switching patients using Privigen®?

- In general, no. If a hospital is meeting the desired share split given in CL 2020-50, then there is no need to consider switching Privigen® patients to another product.
- For patients using Privigen® 2.5g vials, if demand continues unchanged, Privigen® 2.5g vials may not be available in July 2021. Other brands are available in small vial sizes.

Will vial sizes automatically be substituted when I place an order?


- No. If you order a product that is not available, your regional Canadian Blood Services site will contact you to discuss alternatives.

Overall, Privigen® supply should be sufficient to meet demand. We sincerely appreciate all efforts with this change of inventory and will continue to provide customers with Ig product as needed.

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at [www.blood.ca](http://www.blood.ca) in the “Hospitals Services” section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,

A handwritten signature in black ink, appearing to read 'S. Grenier', written in a cursive style.

Sylvain Grenier,  
Director, Plasma Protein and Related Products Formulary Program